Adapting Alzheimer's Disease Modifying Treatment Criteria to Accommodate Adults with Down Syndrome

Matthew P. Janicki, Ph.D.
University of Illinois Chicago
mjanicki@uic.edu
... and National Task Group on Intellectual Disabilities and Dementia Practices

36th Global Conference of Alzheimer's Disease International – Kraków, Poland – April 24, 2024
Disclosures

• No conflicts.

• Underwriting for this effort was provided by the Lumind IDSC Foundation and the National Task Group on Intellectual Disabilities and Dementia Practices in the United States.
Project Management/Coordination Team (LuMind IDSC/NTG Members)

Hampus Hillerstrom  
President & CEO  
LuMind IDSC

Dr. Richard Fisher  
Chief Scientific Officer  
LuMind IDSC

Dr. Matthew Janicki  
Co-President/Board  
NTG

Lois Kelly, RN, MS  
VP, Clinical Operations  
LuMind IDSC

Amit Das  
Sr. Manager, Strategy & Research  
LuMind IDSC

Dr. David Michelson  
Clinical Consultant  
LuMind IDSC
Expert Panel

Dr. Brian Chicoine
Advocate Health
Chicago USA

Dr. Juan Fortea
Biomedical Research Institute Sant Pau
Barcelona Spain

Dr. Forrest Foster
UC Health, University of Cincinnati, USA

Dr. Sigan Hartley
University of Wisconsin, USA

Dr. Seth Keller
NTG, Neurology Advocates
New Jersey USA

Dr. Sharon Krinsky-Mchale
New York State Institute for Basic Research in Developmental Disabilities

Dr. Florence Lai
Massachusetts General Hospital
Boston USA

Dr. Johannes Levin
Ludwig-Maximilians University
Germany

Dr. Anne-Sophie Rebillat
Institut Jerome Lejeune
Paris France

Dr. Diana Rosas
Massachusetts General Hospital
Boston USA

Dr. André Strydom
King’s College
London

Dr. Shahid Zaman
Cambridge University
What are the key issues?

With the emergence of the novel anti-amyloid medications, what are the concerns related to adults with neuroatypical conditions (including DS-AD)?

• **Equity in clinical trials**
  • Absence of any participation in extant clinical trials and thus assurances of efficacy of the medications and safety for their use

• **Prescribing criteria issues**
  • Current language in drug formularies does not provide inclusion for adults with neuroatypical condition

• **Dx for eligibility**
  • Inadequate inclusion of specialty tests for dx of AD in adults with neuroatypical conditions or recognition of potential variations in testing criteria
Why equity for Down syndrome?

Adults with Down syndrome are at high risk of Alzheimer’s disease (and dx’d with DS-AD)

New AD disease modifying treatments have potential to help adults with Down syndrome who meet eligibility criteria

Prescribing criteria either deny access or neglect to acknowledge access options for adults with Down syndrome

Once safety determined there should be no barriers to equal access
Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome

Patients with DS/ID are implicitly not covered by the prior authorization criteria for AD DMTs, potentially depriving them of access to a beneficial treatment.

An international expert panel convened and recommended modified prescriber criteria, ensuring their suitability for DS/ID patients once the drugs are deemed safe for use with this group.

Many patients with DS/ID show younger age dementia onset and floor effects on AD diagnostic assessments, compared to adults with sporadic AD.

**Recommendations** to extant prescribing criteria include:

- **lowering the age** of eligibility (<50)
- **using alternative measures** for diagnosis and neurocognitive decline relevant to DS/ID (specialized DS/ID instruments)
- **broadening latitude** in presentation due to lifelong cognitive limitations (recognizing behavioral variants)
- **raising clinician proficiencies** in diagnosing dementia in adults with DS/ID (continuing education)
What did we do to advocate for equity?

• Identified barriers to equitable access in language of state drug formularies
• Organized a response by convening an expert panel to identify equivalencies to existing language
• Worked with advocacy organizations, governmental authorities, and the medical sphere to alert them to this problem
• Arrived at consensus on equivalencies for determination of presence of Alzheimer’s dementia, appropriate tests, and functional impairments
• Distributed report and published findings in professional journal
Where AD-DMTs are available

• Academab (Aduhelm™) had limited use in the USA and was withdrawn from use by Biogen in January 2024.

• Lecanemab (Leqembi™) has been approved
  
  • In the USA for general use and its payments are covered for all enrollees in Medicare (CMS, 2023)

  • In Japan, approved for adults enrolled in its National Health Insurance program (Igarashi et al., 2023; Japan Times, 2023)

  • In China, approved by the National Medical Products Administration (Biogen, 2023)
Where AD-DMTs are available

- Academab (Aduhelm™) had limited use in the USA and was withdrawn from use by Biogen in January 2024.
- Lecanemab (Leqembi™) has been approved
  - In the USA for general use and its payments are covered for all enrollees in Medicare (CMS, 2023)
  - In Japan, approved for adults enrolled in its National Health Insurance program (Igarashi et al., 2023; Japan Times, 2023)
  - In China, approved by the National Medical Products Administration (Biogen, 2023)
- Approval pending in numerous countries and regions
  - In the EU, under review by the European Medicines Agency (BioArtic, 2023)
  - In Canada, under review by Health Canada (Watt et al., 2023)
  - In Great Britain, lecanemab has been designated for the Innovative Licensing and Access Pathway (ILAP), which aims to reduce the time to market for innovative medicines (Biogen, 2023)
- Donanemab (Sims et al., 2023) is pending approval in 2024 in the USA and in other countries (McKie, 2023)
- In the UK, the Medicines & Healthcare Products Regulatory Agency (MHRA) will decide if lecanemab and donanemab are safe and effective, then the National Institute for Health and Care Excellence (NICE) will decide whether the cost for the medications will be covered.
Outcomes

• Tracking language in prescribing criteria to assure inclusion of Down syndrome
• Promoting equity in upcoming clinical trials
• Alerts to Pharm re: ensuring no barriers are inherent in clinical materials distributed to prescribers
• Preparing constituencies (DS/ID families, associations, etc.) to better understand potential value of access to AD DMTs
• Providing materials to countries where AD DMTs are not yet approved so equity can be on table and DS/ID organizations can advocate for inclusion
Last words

• Advocate for inclusion of adults with intellectual disability/Down syndrome in clinical trials
• Assure investment in trials that produce outcomes for adults with Down syndrome
• Work proactively to have policies of national bodies approving or overseeing use of the AD DMTs to be neutral or not exclusionary
• Aid professional organizations mount education of prescribers on assessing/diagnosing adequately AD in adults with neuroatypical conditions, including Down syndrome/intellectual disability
• Provide counsel to families and persons affected as to the risk/benefits of seeking out AD DMTs
FMI

mjanicki@uic.edu

www.the-ntg.org